How a Patient Centric Approach to Clinical Trials can Revolutionise Drug Discovery
Kindly Sponsored and Hosted by Ipsen

Delivered Digitally on Tuesday 2 June 2020
OBN Digital Events:
How a Patient Centric Approach to Clinical Trials can Revolutionise Drug Discovery

Kindly supported and hosted by


 

Event Outline:
In the past there has been minimal engagement with patients during clinical trials, and a perceived lack of clarity around how patients can have a positive impact in medicine discovery, research and development. 

Expert speakers at this BioTuesday will provide insight into how placing patients at the heart of the drug development process, can greatly increase the chances of long-term success. They will also address how understanding patient needs, insights, values and expectations can be critical components to both the scientific discovery process and real-world application of treatments.

Areas to be addressed include:
- Where are we now with clinical trial delivery? What are the issues and how can a ‘patient centric’ approach encourage positive change?
- The importance of Patient Organisations – what are they and why are they essential for patient recruitment and retention?
- What modals of engagement are most common in a patient centric approach within clinical trials?
- How can emerging technology and AI be used support patients in clinical trials, and what impact do they have on the speed and outcome of trials
- How open communication about patient commonalities is key to developing best practice in clinical trials across therapeutic areas
- Does a ‘patient-centric’ approach impact regulatory & compliance factors? 
- What are the perceived challenges of a patient centric approach?

We will also hear case studies from companies who have implemented a Patient Centric approach to their clinical trial model, and hear how this has positively impacted the study results. 



Event Host:
John Chaddock,
 Vice President, Head of Neuroscience Therapeutic Area Operations & Site Head, Ipsen


Keynote Speakers:
Oleksandr Gorbenko, Global Patient Centricity Director, Ipsen
Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics, Department of Oncology, Medical Sciences Division
Mark Duman, Chief Patient Officer, Ampersand Health
Kristi Clark, Senior Vice President, Project Management and Clinical Operations- Rare and Orphan Solutions, Precision for Medicine



About OBN Digital Events:

This BioTuesday digital edition will be pre-recorded 'as live', and made vavailable for viewing by registered delegates from 08:00 – 20:00 BST on Tuesday 2 June 2020.

A Q&A session will follow the keynote presentations, and we welcome audience questions in advance of the event. Please send your questions to events@obn.org.uk by Monday 25 May and our speakers will answer them during the Q&A session of the recording.

Virtual partnering will be available for registered delegates between 15:00 – 18:00 BST on Tuesday 2 June 2020. Registered delegates can take part in 15-minute 1:1 meetings, which can be requested and scheduled in the run up to the event.

Organisers   Contact    
OBN (UK) Ltd
5F Park Square
Milton Park
Abingdon
OX14 4RR
 
General Enquiries
E: 
info@obn.org.uk
T: +44 (0)1235 420870


 
   
© 2019, All Rights Reserved. OBN (UK) Ltd. Is A Limited Company Registered In England & Wales, Company No. 06618658. VAT No. 935 2567 09
Processing. Please wait.
Loading...